VDs anförande i samband med Infant Bacterial Therapeutics årsstämma
06 mai 2021 12h50 HE
|
Infant Bacterial Therapeutics AB
Verkställande direktören Staffan Strömbergs anförande i samband med IBTs årsstämma 2021 kan ses här Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) (“IBT”) är ett...
Annual General Meeting of Infant Bacterial Therapeutics CEO speech
06 mai 2021 12h50 HE
|
Infant Bacterial Therapeutics AB
CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish. About Infant Bacterial Therapeutics ABInfant Bacterial Therapeutics AB (publ) is a...
Årsstämma i Infant Bacterial Therapeutics
04 mai 2021 11h00 HE
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2021 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen,att ingen utdelning lämnas,beviljad...
Annual General Meeting of Infant Bacterial Therapeutics
04 mai 2021 11h00 HE
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: adoption of the annual reportthat no dividend is...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2021
04 mai 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför vi en fas III-studie (“The Connection Study”) vilket är den sista fasen av vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414 som innehåller...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2021
04 mai 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing...
Infant Bacterial Therapeutics utökar The Connection Study och inkluderar spädbarn med en födelsevikt under 750 gram
29 avr. 2021 16h00 HE
|
Infant Bacterial Therapeutics AB
Efter granskning av Data Monitoring Committee utökar Infant Bacterial Therapeutics “The Connection Study” till att omfatta för tidigt födda barn med en födelsevikt från 500 g till 1000 g. Data...
Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams
29 avr. 2021 16h00 HE
|
Infant Bacterial Therapeutics AB
After the Data Monitoring Committees’ review Infant Bacterial Therapeutics expands the enrollment criteria of The Connection Study to include 500 - 1000 gram birth weight premature infants. The...
Infant Bacterial Therapeutics erhåller ytterligare patentskydd i Kina
15 avr. 2021 13h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) tillkännager idag att det Kinesiska patentmyndigheten har beslutat utfärda ett godkännande av IBTs patentansökan: “A method of activating lactic acid bacteria”,...
Infant Bacterial Therapeutics receives additional patent protection in China
15 avr. 2021 13h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid...